Form 4: CFO Glenn David's PAHC Stock Transactions

Phibro Animal Health CFO Glenn David reported the settlement of restricted stock units and subsequent sale of shares for tax obligations.

Summary

• CFO Glenn David acquired 30,000 shares of Class A Common Stock on February 9, 2026, through the settlement of Restricted Stock Units (RSUs).
• Following this, David sold 12,528 shares of Class A Common Stock on February 11, 2026, at a weighted average price of $51.625 per share, to cover tax withholding obligations related to the RSU vesting.
• The sales occurred in multiple transactions at prices ranging from $51.54 to $52.03.
• After these transactions, David directly beneficially owns 52,317 shares of Class A Common Stock.
• David was originally granted 300,000 RSUs on February 9, 2024, with 150,000 time-vesting and 150,000 performance-vesting.
• 240,000 derivative securities (RSUs) remain beneficially owned by David.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting a routine vesting of executive compensation and continued alignment of the CFO's interests with the company's long-term performance, despite the necessary sale for tax purposes.

Positives

• CFO Glenn David received 30,000 shares of Class A Common Stock from the vesting of Restricted Stock Units, indicating a successful vesting event.
• The initial grant of 300,000 RSUs on February 9, 2024, aligns management incentives with long-term shareholder value, with 150,000 performance-vesting RSUs tied to stock price achievement up to $60 and above.

Negatives

• CFO Glenn David sold 12,528 shares of Class A Common Stock at a weighted average price of $51.625 to satisfy tax withholding obligations, which reduces his direct ownership.

Future Outlook

The remaining 240,000 Restricted Stock Units (RSUs) held by CFO Glenn David are subject to future vesting, with 150,000 time-vesting RSUs vesting in equal installments over the next five anniversaries from the February 9, 2024 grant date, and 150,000 performance-vesting RSUs contingent on the company's stock price reaching between $20 and $60 or above by February 9, 2029.

Management Comments

• The reporting person undertakes to provide to Phibro Animal Health Corporation, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through Restricted Stock Units (RSUs) with both time and performance-based vesting, is a common practice in the animal health industry and broader corporate landscape. This structure aims to align executive incentives with long-term company performance and shareholder value creation, a standard approach for retaining key talent like a Chief Financial Officer.

Comparison to Industry Standards

• The use of a cashless exercise program for tax withholding is a standard industry practice for executive equity compensation, similar to programs seen at companies like Zoetis Inc. or Elanco Animal Health.
• The combination of time-based and performance-based RSUs is a common structure for executive compensation plans across various sectors, including pharmaceuticals and biotechnology, reflecting best practices in corporate governance for aligning executive pay with both tenure and strategic objectives.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sale by the CFO are routine and demonstrate the ongoing alignment of executive incentives with shareholder value through equity compensation. The performance-based RSUs tie a portion of the CFO's compensation directly to stock price appreciation.
• Employees: The filing details executive compensation, which can serve as a benchmark or indicator of the company's overall compensation philosophy.

Next Steps

• Future vesting of 240,000 remaining Restricted Stock Units (RSUs) held by Glenn David, subject to time and performance conditions.
• Continued service of Glenn David as Chief Financial Officer to meet vesting requirements.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and the subsequent sale of shares to cover tax obligations. Such transactions are generally expected and do not typically indicate a change in the company's fundamental outlook or the insider's confidence. The remaining significant RSU holdings, including performance-based units, suggest continued alignment of the CFO's interests with long-term shareholder value. Therefore, a "hold" recommendation is appropriate as this filing does not present new information warranting a change in investment thesis.

Keywords

PHIBRO ANIMAL HEALTH CORP, PAHC, Glenn David, CFO, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Vesting, Equity Compensation, Tax Withholding, Share Sale